Tranexamic Acid Is Safe in Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty
Tranexamsäure ist bei Patient:innen mit venöser Thromboembolie in der Vorgeschichte nach Totalendoprothese sicher
Journal of Bone and Joint Surgery · 03.01.2024 · 106 (1) · 30-38
DOI: 10.2106/jbjs.23.00254 ↗Auf einen Blick
Bei 70.759 Hochrisiko-Patient:innen nach Total Joint Arthroplasty war Tranexamsäure nicht mit mehr Lungenembolie, Schlaganfall oder Myokardinfarkt verbunden. Transfusionen und 90-Tage-Wiederaufnahmen waren seltener.
Fragestellung
Ist Tranexamsäure bei Patient:innen mit früherer venöser Thromboembolie nach Total Joint Arthroplasty mit mehr thromboembolischen Komplikationen verbunden?
Methode
Datenbankstudie mit Patient:innen nach primärer, elektiver TJA von 2015 bis 2021 aus der Premier Healthcare Database; Vergleich TXA vs. kein TXA; adjustierte Regressionen.
Ergebnisse
70.759 Patient:innen; 46.074 erhielten TXA, 24.685 nicht. PE: adjustiertes OR 0,90 (95 %-KI 0,79–1,02); Schlaganfall: 0,97 (0,69–1,37); MI: 0,93 (0,69–1,24). Transfusion: 0,42 (0,38–0,46); 90-Tage-Wiederaufnahme: 0,87 (0,80–0,94).
Schlussfolgerung der Autor:innen
Die Autor:innen schlussfolgern, dass TXA bei ausgewählten Hochrisiko-Patient:innen ohne erhöhtes Risiko für postoperative PE, Schlaganfall oder MI eingesetzt werden kann.
Kernaussagen
- Kein erhöhtes Risiko für PE, Schlaganfall oder MI unter TXA
- Weniger Transfusionen unter TXA
- Weniger 90-Tage-Wiederaufnahmen unter TXA
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bone and Joint Surgery, online erschienen am 15.11.2023. Verfasst von Mary K Richardson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California. Hauptthemen laut MEDLINE: Tranexamic Acid, Venous Thromboembolism, Antifibrinolytic Agents, Arthroplasty, Replacement, Knee. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Tranexamic acid (TXA) is increasingly utilized during total knee arthroplasty (TKA) and total hip arthroplasty (THA) to decrease blood loss; however, there are concerns with regard to potential thromboembolic complications, particularly in high-risk patients. This study sought to define a subset of patients at elevated risk for thromboembolic complications following total joint arthroplasty (TJA) and to compare postoperative outcomes between patients who received TXA and those who did not.
Methods
Patients who underwent primary, elective TJA from 2015 to 2021 were identified in the Premier Healthcare Database. Patients with a history of venous thromboembolism, defined as a history of pulmonary embolism or deep vein thrombosis, were identified and formed the high-risk cohort. Patient demographic characteristics, hospital factors, patient comorbidities, antithrombotic medication use, perioperative blood transfusion, and 90-day complications were assessed and compared between patients who received TXA and those who did not. Univariate regression and multivariable regression were performed to account for potential confounders.
Results
The high-risk cohort comprised 70,759 patients who underwent TJA, of whom 46,074 (65.1%) received TXA and 24,685 (34.9%) did not. After controlling for confounding factors, patients in the TXA cohort had similar risks of pulmonary embolism (adjusted odds ratio [OR], 0.90 [95% confidence interval (CI), 0.79 to 1.02]; p = 0.097), stroke (adjusted OR, 0.97 [95% CI, 0.69 to 1.37]; p = 0.867), and myocardial infarction (adjusted OR, 0.93 [95% CI, 0.69 to 1.24]; p = 0.614) compared with patients who did not receive TXA. Patients who received TXA demonstrated decreased risks of transfusion (adjusted OR, 0.42 [95% CI, 0.38 to 0.46]; p < 0.001) and 90-day readmission (adjusted OR, 0.87 [95% CI, 0.80 to 0.94]; p < 0.001).
Conclusions
TXA utilization was not associated with an increased risk of postoperative pulmonary embolism, stroke, or myocardial infarction in patients with a history of venous thromboembolism. Furthermore, patients who received TXA had a decreased risk of transfusion and readmission. This evidence suggests that TXA may be safely utilized among select high-risk patients. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California.
ORCID-Profile: Mary K Richardson, Kevin C Liu, Cory K Mayfield, Natalie M Kistler, Jay R Lieberman, Nathanael D Heckmann
Zitieren
APA
Richardson, M. K., Liu, K. C., Mayfield, C. K., Kistler, N. M., Lieberman, J. R., & Heckmann, N. D. (2024). Tranexamic Acid Is Safe in Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty. Journal of Bone and Joint Surgery, 106(1), 30-38. https://doi.org/10.2106/jbjs.23.00254
Vancouver
Richardson MK, Liu KC, Mayfield CK, Kistler NM, Lieberman JR, Heckmann ND. Tranexamic Acid Is Safe in Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty. Journal of Bone and Joint Surgery. 2024;106(1):30-38. doi:10.2106/jbjs.23.00254
BibTeX
@article{Richardson2024,
author = {Richardson, Mary K and Liu, Kevin C and Mayfield, Cory K and Kistler, Natalie M and Lieberman, Jay R and Heckmann, Nathanael D},
title = {Tranexamic Acid Is Safe in Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty},
journal = {Journal of Bone and Joint Surgery},
year = {2024},
volume = {106},
number = {1},
pages = {30--38},
doi = {10.2106/jbjs.23.00254}
}
EUVIMED